For the year ending 2025-12-31, APH made $23,094,700K in revenue. $4,270,300K in net income. Net profit margin of 18.49%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net sales | 23,094,700 | 15,222,700 | 12,554,700 | 12,623,000 |
| Cost of sales | 14,577,000 | 10,083,000 | 8,470,600 | 8,594,800 |
| Gross profit | 8,517,700 | 5,139,700 | 4,084,100 | 4,028,200 |
| Acquisition-related expenses | 103,400 | 127,400 | 34,600 | 21,500 |
| Selling, general and administrative expenses | 2,545,700 | 1,855,400 | 1,489,900 | 1,420,900 |
| Operating income | 5,868,600 | 3,156,900 | 2,559,600 | 2,585,800 |
| Interest expense | 367,800 | 217,000 | 139,500 | 128,400 |
| Gain on bargain purchase acquisition | 0 | 0 | 5,400 | - |
| Other income (expense), net | 99,900 | 72,000 | 29,300 | 10,000 |
| Income before income taxes | 5,600,700 | 3,011,900 | 2,454,800 | 2,467,400 |
| Provision for income taxes | 1,295,400 | 570,300 | 509,300 | 550,600 |
| Net income from continuing operations | - | - | 1,945,500 | 1,916,800 |
| Less net income from continuing operations attributable to noncontrolling interests | - | - | 17,500 | 14,500 |
| Net income from continuing operations attributable to amphenol corporation | - | - | 1,928,000 | 1,902,300 |
| Net income | 4,305,300 | 2,441,600 | - | - |
| Income from discontinued operations attributable to amphenol corporation, net of income taxes of (3.2) for 2021 | - | - | 0 | 0 |
| Less net income attributable to noncontrolling interests | 35,000 | 17,600 | - | - |
| Net income attributable to amphenol corporation | 4,270,300 | 2,424,000 | 1,928,000 | 1,902,300 |
| Earnings per share, basic | 3.51 | 2.01 | 3.23 | 3.19 |
| Earnings per share, diluted | 3.34 | 1.92 | 3.11 | 3.06 |
| Weighted average number of shares outstanding, basic | 1,218,200,000 | 1,203,800,000 | 596,500,000 | 596,200,000 |
| Weighted average number of shares outstanding, diluted | 1,277,500,000 | 1,263,600,000 | 620,600,000 | 621,000,000 |
AMPHENOL CORP DE (APH)
AMPHENOL CORP DE (APH)